E09.3543 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral

Name of the Condition

• Drug or Chemical Induced Diabetes Mellitus with Proliferative Diabetic Retinopathy with Combined Traction Retinal Detachment and Rhegmatogenous Retinal Detachment, Bilateral (ICD-10 Code: E09.3543)

Summary

This condition is a form of diabetes mellitus resulting from drug or chemical exposure, characterized by advanced diabetic eye disease. It involves proliferative diabetic retinopathy, where abnormal blood vessel growth in the retina leads to combined traction and rhegmatogenous retinal detachments in both eyes, potentially causing significant vision loss.

Causes

The condition is induced by exposure to drugs or chemicals that disrupt glucose metabolism, leading to uncontrolled hyperglycemia. These substances impair insulin regulation, triggering diabetes that progresses to proliferative diabetic retinopathy. The retinal detachments occur due to abnormal vascular growth and structural changes in the retina.

Risk Factors

• Use of medications or exposure to chemicals known to affect glucose metabolism.
• Pre-existing diabetes or family history of diabetes.
• Long-standing diabetes or poorly controlled blood sugar levels.
• Other risk factors for diabetic retinopathy, such as hypertension or kidney disease.

Symptoms

• Blurred vision or sudden vision loss in both eyes.
• Floaters or dark spots in the visual field of both eyes.
• Distorted or wavy vision in both eyes.
• Pain or redness in the eyes (less common).

Diagnosis

Diagnosis involves a comprehensive eye examination, including dilated retinal imaging (e.g., fundus photography or optical coherence tomography) to assess retinal changes. Blood tests may confirm hyperglycemia and drug/chemical exposure. Fluorescein angiography can evaluate abnormal blood vessel growth. Bilateral involvement is confirmed by examining both eyes.

Treatment Options

Treatment focuses on managing diabetes (e.g., discontinuing the offending agent, glycemic control) and addressing retinal detachment. Options include laser photocoagulation, intravitreal injections (e.g., anti-VEGF agents), or surgery (e.g., vitrectomy) to repair detachments. Bilateral cases may require sequential or simultaneous interventions.

Prognosis and Follow-Up

Prognosis depends on early intervention and glycemic control. Vision loss may be irreversible if detachments are severe. Regular follow-up with an ophthalmologist is critical to monitor retinal changes and adjust treatment. Bilateral involvement increases the risk of permanent vision impairment.

Complications

• Permanent vision loss or blindness.
• Recurrent retinal detachments.
• Glaucoma or cataracts.
• Worsening diabetic retinopathy.

Lifestyle & Prevention

• Avoid or discontinue exposure to causative drugs/chemicals.
• Maintain strict blood sugar control.
• Regular eye exams for early detection.
• Manage comorbidities (e.g., hypertension) to reduce retinopathy risk.

When to Seek Professional Help

Seek immediate care for sudden vision changes, floaters, or eye pain. Regular ophthalmologic evaluations are essential for those with drug/chemical-induced diabetes or known retinopathy risk factors.

Tips for Medical Coders

Document the bilateral nature of the retinal detachment and confirm the drug/chemical-induced diabetes etiology. Ensure clinical notes specify proliferative diabetic retinopathy with combined traction and rhegmatogenous detachments in both eyes to support code E09.3543.